Article thumbnail

First report of molecular detection of fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium tuberculosis isolates in Kuwait

By Noura M Al-Mutairi, Suhail Ahmad and Eiman Mokaddas
Topics: Short Report
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). AA: Rapid detection of ethambutol-resistant Mycobacterium tuberculosis strains by PCR-RFLP targeting embB codons 306 and 497 and iniA codon 501 mutations. Mol Cell Probes
  2. (2002). Abal AT: Molecular fingerprinting of isoniazidresistant Mycobacterium tuberculosis isolates from Chest Diseases Hospital in Kuwait. Microbiol Immunol
  3. (2008). Ahmad S: Species spectrum of nontuberculous mycobacteria isolated from clinical specimens in Kuwait. Curr Microbiol
  4. (2009). Altraja A: Predictors of poor treatment outcome in multi and extensively drug-resistant pulmonary TB. Eur Respir J
  5. (2003). American Thoracic Society, CDC, Infectious Disease Society of America: Treatment of tuberculosis. Morb Mort Weekly Rep
  6. (2009). AP: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis
  7. (2001). D: Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements.
  8. (2007). Development and evaluation of a multiplex PCR for rapid detection and differentiation of Mycobacterium tuberculosis complex members from non-tuberculous mycobacteria.
  9. (2002). Enarson DA: Epidemiology of tuberculosis in Kuwait from 1965 to 1999. Int J Tuberc Lung Dis
  10. (2002). Fares E: Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn Microbiol Infect Dis
  11. (2005). Fattorini L: Evaluation of a line probe assay for the rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother
  12. (2009). Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.
  13. (2008). Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis
  14. (2009). for the Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Epidemiology of antituberculosis drug resistance 2002-2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet
  15. (2006). G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet
  16. (2011). Kirikae T: Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis.
  17. (2010). MB: Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis
  18. (2008). MC: Comprehensive treatment of extensively drug-resistant tuberculosis.
  19. (2007). Mokaddas E: Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis
  20. (2009). Mokaddas E: Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Ann Clin Microbiol Antimicrob
  21. (2011). Mokaddas E: New challenges in the treatment of tuberculosis in the 21 st century. Treat Strat Resp
  22. (2009). Mokaddas E: Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Resp Med
  23. (2005). Mokaddas E: The occurrence of rare rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from Kuwait. Int J Antimicrob Agents
  24. (2008). Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother
  25. (2010). New approaches in the diagnosis and treatment of latent tuberculosis infection. Resp Res
  26. Organization: Anti-tuberculosis drug resistance in the world: fourth Global report.
  27. (2010). Organization: Global tuberculosis control:
  28. (2010). Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB):
  29. (2010). RCY: Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and metaanalysis.
  30. (1997). Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA
  31. (2009). Rigouts L: High level cross-resistance between kanamycin, amikacin and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother
  32. (1996). Samir I: Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait,
  33. (2006). Sugawara I: Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing.
  34. (2005). TM: Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother
  35. W: Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007, 4:article no.
  36. (2003). WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis
  37. (2007). Yang PC: Fluoroquinolones resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.